<DOC>
	<DOCNO>NCT00252486</DOCNO>
	<brief_summary>The purpose study test hypothesis flax oil , omega-3 fatty acid , superior placebo maintenance treatment bipolar disorder child adolescent . Our primary objective determine flax oil efficacious pediatric bipolar population reduce symptom mania depression . A secondary objective examine fatty acid level predictor treatment response symptom severity . This clinical trial evaluate whether supplementation flax oil , contain omega-3 fatty acid alpha-linolenic acid ( alpha-LNA ) , safely reduce symptom severity youth bipolar disorder .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Children Adolescents With Bipolar Disorder</brief_title>
	<detailed_description>Pediatric bipolar disorder difficult-to-treat recurrent mental illness characterize predominant mood state irritability , often mixed , rapid-cycling , psychotic symptom . Results randomize controlled trial lithium , valproic acid , antipsychotic early onset bipolar disorder offer hope improvement many , yet also demonstrate need additional treatment option child respond adequately , tolerate , first-line mood stabilizer alone combination atypical antipsychotic . As popular over-the-counter dietary supplement , omega-3 fatty acid represent appeal option treatment young bipolar population likely well tolerate cost less compare conventional mood stabilize agent . In addition , appeal parent adolescent due perception 'natural ' substance relative lack systemic side effect . To knowledge , prospective , randomize , control trial flax oil treatment bipolar disorder selectively evaluate omega-3 fatty acid child adolescent bipolar population . Children adolescent age 6-17 year symptomatic Bipolar I II disorder ( n=51 ) , manic , hypomanic , mixed , depressed , randomize either flax oil capsule contain 550 mg alpha-linolenic acid per 1 gram olive oil placebo adjunctively monotherapy . Doses titrate 12 capsule per day tolerate 16 week . Primary outcome include change Young Mania Rating Scale ( YMRS ) , Child Depression Rating Scale-Revised ( CDRS-R ) , Clinical Global Impressions- Bipolar ( CGI-BP ) rating use Kaplan-Meier survival analysis . Baseline end-of-study free fatty acid measure examined change relevance effect .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>male female outpatient age 617 DSMIV diagnosis bipolar I II disorder currently symptomatic CGI 3 great , YMRS 4 great , CDRSR 22 great fail stabilization lithium valproate combine therapy therapeutic level document intolerant medication ability willingness provide assent inform write consent least one parent/ legal guardian mental retardation ( IQ less 70 ) comorbid autism , pervasive developmental disorder , history substance abuse positive toxicology screen , acute posttraumatic stress disorder presence serious chronic medical illness inability swallow capsule pregnant sexually active without reliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Bipolar</keyword>
	<keyword>Omega-3 Fatty acid</keyword>
</DOC>